AARTIPHARM — Aarti Pharmalabs Income Statement
0.000.00%
- IN₹66.63bn
- IN₹69.45bn
- IN₹18.53bn
- 54
- 20
- 83
- 54
Annual income statement for Aarti Pharmalabs, fiscal year end - March 31st, INR millions except per share, conversion factor applied.
2021 March 31st | 2022 March 31st | 2023 March 31st | 2024 March 31st | |
---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M |
Source: | Interim Report | Interim Report | ARS | ARS |
Standards: | — | — | IAS | IAS |
Status: | Final | Final | Final | Final |
Revenue | ||||
Total Revenue | 0 | 11,999 | 19,452 | 18,526 |
Cost of Revenue | ||||
Gross Profit | — | 4,748 | 7,755 | 8,319 |
Selling / General / Administrative Expenses | ||||
Research And Development | ||||
Depreciation and Amortization | ||||
Unusual Expense / Income | ||||
Other Operating Expenses | ||||
Total Operating Expenses | 0.046 | 8,793 | 16,653 | 15,398 |
Operating Profit | -0.046 | 3,206 | 2,799 | 3,128 |
Gain / Loss on Sale of Assets | ||||
Total Net Non Operating Interest Income / Expense | ||||
Other Net Non Operating Costs | ||||
Net Income Before Taxes | -0.046 | 1,554 | 2,608 | 3,005 |
Provision for Income Taxes | ||||
Net Income After Taxes | -0.046 | 1,223 | 1,935 | 2,169 |
Net Income Before Extraordinary Items | ||||
Net Income | -0.046 | 1,223 | 1,935 | 2,169 |
Income Available to Common Shareholders Excluding Extraordinary Items | ||||
Income Available to Common Shareholders Including Extraordinary Items | ||||
Diluted Net Income | -0.046 | 1,223 | 1,935 | 2,169 |
Diluted Weighted Average Shares | ||||
Basic EPS Including Extraordinary Items | ||||
Diluted EPS Including Extraordinary Items | ||||
Diluted EPS Excluding Extraordinary Items | ||||
Normalised Income Before Taxes | ||||
Normalised Income After Taxes | ||||
Normalised Income Available to Common Shareholders | ||||
Diluted Normalised EPS | -0.001 | 27 | 21.4 | 23.9 |
Dividends per Share |